Earnings History Data for Ligand Pharmaceuticals Incorporated (LGND) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
27-02-2025	PM		LGND	Ligand Pharmaceuticals Incorporated	2,240	-1.64	0.57	0.79	Ligand Pharmaceuticals beats top-line and bottom-line estimates; reaffirms FY25 outlook [2/27/2025 7:13 AM]	115.96	0.95 (0.83%)	115.75	0.74 (0.64%)	67.72 - 129.90	131,239	110,000	282
Ligand Pharmaceuticals Q4 2024 Earnings Preview [2/26/2025 12:48 PM] Ligand Pharmaceuticals beats top-line and bottom-line estimates; reaffirms FY25 outlook [2/27/2025 7:13 AM] Ligand Reports Fourth Quarter and Full Year 2024 Financial Results [2025-02-27 07:00AM]
07-11-2024	PM		LGND	Ligand Pharmaceuticals Incorporated	2,030	-0.39	0.75	0.71	Ligand Pharmaceuticals beats Q3 top and bottom line estimates [11/7/2024 7:21 AM]	129.38	12.48 (10.68%)	120.01	3.11 (2.66%)	51.21 - 129.51	217,957	130,000	1,809
Ligand Pharmaceuticals Q3 2024 Earnings Preview [11/6/2024 3:37 PM] Ligand Pharmaceuticals beats Q3 top and bottom line estimates [11/7/2024 7:21 AM] Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance [2024-11-07 07:00AM]
06-08-2024	AH		LGND	Ligand Pharmaceuticals Incorporated	1,870	0.92	0.82	1.10	Ligand Pharmaceuticals reports mixed Q2 results; reaffirms FY24 outlook [8/6/2024 5:10 PM]	93.53	-5.51 (-5.56%)	99.04	0.0 (0.00%)	49.24 - 112.12	134,195	140,000	2,806
Ligand Pharmaceuticals reports mixed Q2 results; reaffirms FY24 outlook [8/6/2024 5:10 PM]
07-05-2024	AH		LGND	Ligand Pharmaceuticals	1,280	0.80	1.13	0.00	Ligand Pharmaceuticals Non-GAAP EPS of $1.20 beats by $0.37, revenue of $30.98M beats by $3.06M [5/7/2024 4:52 PM]	80.36	7.14 (9.75%)	73.22	0.0 (0.00%)	49.24 - 94.57	263,172	130,000	6,900
Ligand Pharmaceuticals Non-GAAP EPS of $1.20 beats by $0.37, revenue of $30.98M beats by $3.06M [5/7/2024 4:52 PM] Ligand Pharmaceuticals and Agenus enter into royalty financing deal [5/7/2024 8:02 AM]
27-02-2024	PM		LGND	Ligand Pharmaceuticals Incorporated	1,320	0.79	0.24	-0.26	Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by $2.46M [2/27/2024 7:33 AM]	88.44	14.02 (18.84%)	85.01	10.59 (14.23%)	49.24 - 94.57	705,899	110,000	15,159
Ligand Pharmaceuticals Q4 2023 Earnings Preview [2/26/2024 11:16 AM] Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by $2.46M [2/27/2024 7:33 AM]
08-11-2023	AH		LGND	Ligand Pharmaceuticals Incorporated	923.47	0.71	0.36	-0.20	Ligand Pharmaceuticals Non-GAAP EPS of $1.02 beats by $0.40, revenue of $32.87M beats by $5.65M [11/8/2023 4:43 PM]	54.62	2.40 (4.59%)	52.23	0.0 (0.00%)	49.24 - 85.70	233,298	90,000	2,299
Ligand Pharmaceuticals Non-GAAP EPS of $1.02 beats by $0.40, revenue of $32.87M beats by $5.65M [11/8/2023 4:43 PM]
08-08-2023	AH		LGND	Ligand Pharmaceuticals Incorporated	1,150	1.10	0.39	-0.14	Ligand Pharmaceuticals Non-GAAP EPS of $1.42 beats by $0.76, revenue of $26.4M beats by $0.67M [8/8/2023 5:42 PM]	70.67	3.55 (5.28%)	66.74	-0.39 (-0.58%)	47.76 - 85.70	144,679	80,000	2,534
Ligand Pharmaceuticals Non-GAAP EPS of $1.42 beats by $0.76, revenue of $26.4M beats by $0.67M [8/8/2023 5:42 PM]
04-05-2023	AH	4:00 PM ET (May 4)	LGND	Ligand Pharmaceuticals Incorporated	1,280	1.96	0.57	0.15	Ligand Pharmaceuticals Non-GAAP EPS of $2.28 beats by $1.39, revenue of $43.9M beats by $10.35M [5/4/2023 5:01 PM]	79.47	2.77 (3.60%)	76.71	0.0 (0.00%)	45.25 - 85.70	139,243	90,000	3,371
Ligand Pharmaceuticals Non-GAAP EPS of $2.28 beats by $1.39, revenue of $43.9M beats by $10.35M [5/4/2023 5:01 PM] Ligand Pharma up 5% after hours on 2023 guidance boosts [5/4/2023 6:56 PM]
22-02-2023	AH	4:00 PM ET (Feb 22)	LGND	Ligand Pharmaceuticals Incorporated	1,930	-0.26	0.71	1.34	Ligand Pharmaceuticals Non-GAAP EPS of $1.36 beats by $0.24, revenue of $50.38M beats by $10.75M [2/22/2023 4:03 PM]	75.09	2.97 (4.12%)	72.12	0.0 (0.00%)	45.25 - 83.95	137,674	120,000	6,112
Ligand Pharmaceuticals Non-GAAP EPS of $1.36 beats by $0.24, revenue of $50.38M beats by $10.75M [2/22/2023 4:03 PM]
07-11-2022	AH	4:00 PM ET (Nov 7)	LGND	Ligand Pharmaceuticals Incorporated	1,060	-0.20	0.09	1.18	Ligand Pharmaceuticals Non-GAAP EPS of $0.41 misses by $0.02, revenue of $66.09M beats by $27.76M [11/7/2022 4:25 PM]	69.81	6.97 (11.08%)	62.84	0.0 (0.00%)	45.25 - 105.99	254,282	230,000	5,168
Ligand Pharmaceuticals Non-GAAP EPS of $0.41 misses by $0.02, revenue of $66.09M beats by $27.76M [11/7/2022 4:25 PM] Ligand rises 16% as company sees 2022 earnings above estimates [11/8/2022 2:03 PM] Ligand Reports Third Quarter 2022 Financial Results [Nov-07-22 04:01PM]
08-08-2022	AH	4:00 PM ET (Aug 8)	LGND	Ligand Pharmaceuticals Incorporated	1,540	-0.14	0.12	1.16	Ligand Pharmaceuticals Non-GAAP EPS of $1.03 beats by $0.60, revenue of $57.4M beats by $19.67M [8/8/2022 4:34 PM]	102.34	3.09 (3.11%)	99.25	0.0 (0.00%)	72.57 - 169.98	77,989	90,000	5,380
Ligand Pharmaceuticals Non-GAAP EPS of $1.03 beats by $0.60, revenue of $57.4M beats by $19.67M [8/8/2022 4:34 PM] Ligand Reports Second Quarter 2022 Financial Results [Aug-08-22 04:01PM]
04-05-2022	AH	4:00 PM ET (May 4)	LGND	Ligand Pharmaceuticals	1,566	0.15	0.61	0.00	Ligand Pharmaceuticals Non-GAAP EPS of $0.76 beats by $0.10, revenue of $45.69M beats by $11.48M [5/4/2022 4:52 PM]	90.28	-5.72 (-5.96%)	96.00	0.0 (0.00%)	88.11 - 169.98	268,991	160,000	1,073
Ligand Pharmaceuticals Non-GAAP EPS of $0.76 beats by $0.10, revenue of $45.69M beats by $11.48M [5/4/2022 4:52 PM] Ligand Reports First Quarter 2022 Financial Results [May-04-22 04:01PM] Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates [May-04-22 08:55PM] Ligand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on Track [May-05-22 11:22AM]
17-02-2022	AH	4:00 PM ET (Feb 17)	LGND	Ligand Pharmaceuticals Incorporated	2,010	1.34	0.97	1.20	Ligand Pharmaceuticals Non-GAAP EPS of $1.80 beats by $0.43, revenue of $72.5M beats by $7.41M [2/17/2022 4:04 PM]	103.32	-8.89 (-7.92%)	111.00	-1.21 (-1.08%)	99.01 - 172.19	405,704	130,000	3,813
Medical Stocks' Q4 Earnings on Feb 17: RGEN, IRWD & More [Feb-16-22 09:11AM] Ligand Reports Fourth Quarter and Full Year 2021 Financial Results [Feb-17-22 04:01PM] Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22 [Feb-18-22 11:14AM]
09-11-2021	AH	4:00 PM ET (Nov 9)	LGND	Ligand Pharmaceuticals Incorporated	2,630	1.18	0.61	0.71	Ligand Pharmaceuticals EPS beats by $0.54, beats on revenue [11/9/2021 4:04 PM]	165.88	14.00 (9.22%)	160.50	8.62 (5.68%)	79.52 - 219.75	308,139	130,000	1,413
Ligand Pharmaceuticals EPS beats by $0.54, beats on revenue [11/9/2021 4:04 PM] Benchmark keeps buy rating on Ligand following Q3 2021 earnings beat; shares up 7% [11/10/2021 9:50 AM] Ligand Reports Third Quarter 2021 Financial Results [Nov-09-21 04:02PM] Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company [Nov-09-21 04:01PM] Ligand Pharmaceuticals (LGND) Beats Q3 Earnings and Revenue Estimates [Nov-09-21 06:15PM] Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript [Nov-10-21 12:32AM] Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb [Nov-10-21 09:26AM] Ligand To Spin-Off OmniAb Platform Into Its Own Independent Company [Nov-10-21 12:23PM] The SEC Wins Mixed Verdict Against a Short Seller Who Wouldnt Settle [Nov-10-21 05:47PM]
29-07-2021	AH	4:00 PM ET (Jul 29)	LGND	Ligand Pharmaceuticals Incorporated	2,030	1.16	1.15	0.65	Ligand Pharmaceuticals EPS beats by $0.27, beats on revenue; updates full year guidance [7/29/2021 4:06 PM]	113.71	-5.25 (-4.41%)	118.96	0.0 (0.00%)	78.26 - 219.75	120,614	130,000	22,166
Ligand Pharmaceuticals EPS beats by $0.27, beats on revenue; updates full year guidance [7/29/2021 4:06 PM] Landing AI's LandingLens visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration antibody discovery platforms [Jul-28-21 04:00PM] Would Shareholders Who Purchased Ligand Pharmaceuticals' (NASDAQ:LGND) Stock Three Years Be Happy With The Share price Today? [Jul-28-21 05:47AM] Ligand Reports Second Quarter 2021 Financial Results [Jul-29-21 04:01PM] Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Top Estimates [Jul-29-21 06:05PM] Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript [Jul-30-21 02:02AM] Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut [Jul-30-21 10:46AM]
03-05-2021	AH	4:00 PM ET (May 3)	LGND	Ligand Pharmaceuticals Incorporated	2,430	1.03	0.72	0.62	Ligand Pharmaceuticals EPS beats by $0.28, misses on revenue [5/3/2021 4:03 PM]	132.03	-13.20 (-9.09%)	138.00	-7.23 (-4.98%)	78.26 - 219.75	280,906	100,000	1,488
Ligand Pharmaceuticals, Inc. to Host Earnings Call [May-03-21 02:45PM] Ligand Reports First Quarter 2021 Financial Results [May-03-21 04:01PM] Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates [May-03-21 05:20PM] Ligand Pharmaceuticals Inc (LGND) Q1 2021 Earnings Call Transcript [May-04-21 12:00AM] Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug [May-04-21 06:05AM] Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales [May-04-21 11:04AM]
03-02-2021	PM	8:00 AM ET (Feb 3)	LGND	Ligand Pharmaceuticals Incorporated	2,980	1.20	0.77	0.42	Ligand Pharmaceuticals EPS beats by $0.63, beats on revenue [2/3/2021 7:42 AM]	177.74	0.66 (0.37%)	185.50	8.42 (4.75%)	57.24 - 198.79	812,444	1,774,721	4,110
Ligand Pharmaceuticals EPS beats by $0.63, beats on revenue [2/3/2021 7:42 AM] Ligand Pharmaceuticals Q4 2020 Earnings Preview [2/2/2021 1:30 PM] Ligand and Travere announce promising data from late-stage sparsentan trial [2/2/2021 12:45 PM] Ligand Pharmaceuticals: Q4 Earnings Insights [Feb-03-21 07:58AM]
30-10-2020	PM	7:30 AM ET (Oct 30)	LGND	Ligand Pharmaceuticals Incorporated	1,390	0.71	0.81	0.15	Ligand Pharmaceuticals EPS beats by $0.06, misses on revenue [10/30/2020 8:08 AM]	82.63	-0.44 (-0.53%)	83.08	0.01 (0.01%)	57.24 - 127.80	493,830	557,156	264

03-08-2020	PM	8:00 AM ET (Aug 3)	LGND	Ligand Pharmaceuticals Incorporated	2,030	0.65	0.39	0.41	Ligand Pharmaceuticals beats on revenue [8/3/2020 7:31 AM]	117.25	0.07 (0.06%)	120.00	2.82 (2.41%)	57.24 - 127.80	348,973	219,586	14,985

06-05-2020	AH		LGND	Ligand Pharmaceuticals Incorporated	1,540	0.62	0.32	0.97		0.0	0.0 (0.00%)	0.0	0.0 (0.00%)	0.0 - 0.0	0	0	0